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Zika virus (ZIKV) has emerged as a major
health concern. To aid the development
of antivirals, Coloma et al. report high-
resolution crystal structures of the ZIKV
NS5 methyltransferase, one bound to
S-adenosylmethionine and another
bound to S-adenosylmethionine and
7-methyl guanosine diphosphate. The
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The Zika virus (ZIKV) poses a major public health
emergency. To aid in the development of antivirals,
we present two high-resolution crystal structures of
the ZIKV NS5 methyltransferase: one bound to S-ad-
enosylmethionine (SAM) and the other bound to SAM
and 7-methyl guanosine diphosphate (7-MeGpp).We
identify features of ZIKV NS5 methyltransferase that
lend to structure-based antiviral drug discovery.
Specifically, SAM analogs with functionalities on
the Cb atom of the methionine portion of the mole-
cules that occupy the RNA binding tunnel may
provide better specificity relative to human RNA
methyltransferases.INTRODUCTION
The Zika virus (ZIKV) is a member of the Flavivirus genus that in-
cludes other mosquito-borne human pathogens such as dengue
virus (DENV1–4), Murray Valley encephalitis virus (MVEV), West
Nile virus (WNV), yellow fever virus (YFV), and Japanese enceph-
alitis virus (JEV), among others (Petersen et al., 2016). ZIKV has
emerged as amajor health concern over the past year (Fauci and
Morens, 2016; Lazear and Diamond, 2016). Its rapid spread
across the Americas and, in particular, its link to microcephaly
in newborn infants and the Guillain-Barre´ syndrome in adults
has invigorated efforts to develop a vaccine against ZIKV and
to eradicate the Aedes mosquito vectors. An important strategy
for halting the spread of ZIKV in the event of more outbreaks
would be designing antivirals to inhibit viral protein enzymatic
activities central to the lifecycle and survival of the virus.
The flavivirus genome consists of an 11 kB positive-sense
single-stranded RNA that acquires a methylated 50 cap structure
(N7MeGpppA20OMe; Me, methyl group) for stability, efficient trans-
lation, and evasion of the host immune response (Dong et al.,
2014). Both the N7 and 20Omethylation reactions are performedCell Report
This is an open access article undby the same methyltransferase (MTase) domain, located at
the N terminus of the nonstructural protein NS5. The NS5-
MTase methylates first the N7 atom of guanosine and then the
20O of the initiating adenosine of the nascent viral transcript
(GpppA-RNA/ N7MeGpppA-RNA/ N7MeGpppA20OMe-RNA) us-
ing S-adenosylmethionine (SAM) as themethyl donor and gener-
ating S-adenosylhomocysteine (SAH) as the reaction byproduct
(Dong et al., 2014). Crystal structures of several flavivirus NS5-
MTases have been reported bound to various ligands (Bollati
et al., 2009; Egloff et al., 2002, 2007; Yap et al., 2010; Zhao
et al., 2015; Zhou et al., 2007), including SAM/SAH, GTP,
and RNA.
Mutations in NS5-MTase that lead to defects in N7methylation
are lethal in flaviviruses (Dong et al., 2010; Ray et al., 2006; Zhou
et al., 2007), whereas defects in 20Omethylation attenuate the vi-
rus and is a basis for vaccine development (Li et al., 2013; Z€ust
et al., 2013). NS5-MTase has become an attractive target for
the development of antivirals to block cap formation, and several
inhibitors have been reported bound to either the SAM/SAH
binding pocket or the GTP binding pocket (Benarroch et al.,
2004; Chen et al., 2013; Coutard et al., 2014; Lim et al., 2011;
Stahla-Beek et al., 2012). To help guide the discovery of antivi-
rals against ZIKV, we present two high-resolution crystal struc-
tures of NS5-MTase from the French Polynesia strain of the
ZIKV virus. The first structure, determined at 1.33 A˚ resolution,
has SAM bound to the enzyme (NS5-MTaseSAM). The second
structure, determined at 1.50 A˚ resolution, has both SAM and
N7-methyl guanosine diphosphate (7-MeGpp) bound to the
enzyme (NS5-MTaseSAM,7-MeGpp). The high resolution of both
structures makes them well suited for structure-based antiviral
drug discovery.
RESULTS
We expressed and purified ZIKV NS5-MTase (residues 1–266) of
the H/PF/2013 strain as a soluble protein from E. coli. Purified
protein was crystallized at 20C, and the structure was deter-
mined by molecular replacement. Initial maps revealed differ-
ence density in the SAM binding pocket (Figure 1A) despite nos 16, 3097–3102, September 20, 2016 ª 2016 The Author(s). 3097
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Structures of ZIKV NS5-MTase
(A) Structure of ZIKV NS5-MTase bound to SAM. Fo-Fc difference electron
density (contoured at 3s) for SAM is shown as graymesh. Secondary structure
elements are labeled. Ter, terminus.
(B) Structure of ZIKV NS5-MTase bound to SAM and 7-MeGpp. Fo-Fc dif-
ference electron density (contoured at 3s) for SAM and 7MeGpp is shown as
gray mesh.








Space group C 1 2 1 C 1 2 1
Cell Dimensions
a, b, c (A˚) 72.65, 78.14, 45.38 129.34, 77.48, 37.03





Rsym 0.063 (0.280) 0.053 (0.478)
I/s(I) 17.7 (4.1) 7.7 (1.4)
Completeness (%) 91.9 (55.5) 99.0 (99.0)
Redundancy 4.7 (3.5) 1.8 (1.7)
Refinement
Resolution (A˚) 43.40–1.33 36.80–1.50















Bond lengths (A˚) 0.008 0.005
Bond angles () 1.031 0.86
aValues in parentheses are for the highest-resolution shell.intentional addition of the ligand in the purification or crystalliza-
tion buffers. It is common for flavivirus MTases to copurify with
SAM or SAH as, for example, in structures of NS5-MTase from
DENV2 (PDB: 1L9K) (Egloff et al., 2002) and DENV3 (PDB:
3P97) (Lim et al., 2011). The structure of NS5-MTaseSAM was
refined to a resolution of 1.33 A˚, with Rwork and Rfree values of
17.0% and 18.9%, respectively (Table 1). To obtain crystals of
NS5-MTaseSAM,7-MeGpp, SAM and 7-MeGpp were added to pu-
rified ZIKV NS5-MTase in 6-foldmolar excess prior to crystalliza-
tion. The structure of NS5-MTaseSAM,7-MeGpp was determined to
1.50 A˚ with Rwork and Rfree values of 15.9% and 17.9%, respec-
tively (Table 1).
The two structures are nearly identical and superimpose with
an RMSD of 0.21 A˚ for 219 Ca atoms, revealing an enzyme
that is essentially preformed to bind 7-MeGpp (Figure 1). The3098 Cell Reports 16, 3097–3102, September 20, 2016ZIKV NS5-MTase consists of a MTase core (residues 54–223)
with a Rossmann fold, composed of seven b strands (b1–b7)
and four a helices (aX, aA, aD, and aE) (Figures 1 and S1). The
MTase core is flanked by a helices (A1–A4) and b strands (B1–
B2) that form the N- and C-terminal extensions and cradle one
side of the core (Figure 1). SAM binds in a cleft formed by b1,
b2, and aA as well as a loop (amino acids 81–86) that carries
the consensus ‘‘motif 1’’ (GxGxGx; x, usually a small chain amino
acid) characteristic of Rossmann fold methylases (Figures 1A
and 2A). The SAM adenine base is sandwiched between the
Lys105 (partially disordered) and Ile147 side chains, whereas
the N1 and N6 atoms makes hydrogen bond with the backbone
amide of Val132 and side chain of Asp131 (Figure 2A). The ribose
sugar participates in solvent mediated interactions with the
backbone of Gly106 and Glu111 and side chain of Thr104. The
methionine portion of SAM is fixed by interactions with the side
chains of Ser56 and Asp146 as well as the backbone amides
of Gly86 and Trp87. Asp146 is part of the K61-D146-K182-E218
tetrad motif that has been shown to be important for both
N7 and 20O methylation. 7-MeGpp binds in a cleft between the
helices A1, A2, and a loop between b6 and b7 (amino acids
Figure 2. Interactions of ZIKV NS5-MTase with Bound Ligands
(A) Interactions between ZIKV NS5-MTase and SAM. Hydrogen bonds are
depicted as dashed lines. Select solvent molecules are shown as red spheres.
(B) Interactions between ZIKV NS5-MTase and 7-MeGpp.208–218). The 7-MeGpp base packs against the aromatic ring of
Phe24, whereas its exocyclic N6 amino group makes hydrogen
bonds with the main chain carbonyls of Leu16 and Met19 (Fig-
ures 1B and 2B). The diphosphate moiety is fixed by hydrogen
bonds with Lys28, Ser150, Arg213, and Ser215, whereas the
sugar 20O is within hydrogen bonding distance of the side chains
of Lys13 and Asn17. All of these amino acids are conserved in
flaviviruses and underlie almost identical interactions with bound
ligands (Figure S1).
The SAM and 7-MeGpp binding sites are separated by >15 A˚
(Figure 3A). A positively charged tunnel spans two sites where,
based on the structure of DENV3 NS5 with RNA (Zhao et al.,
2015), the ZIKV viral RNA likely binds (Figure 3A) and interacts
with residues Lys28, Arg41, Arg57, Arg84, Glu111, and Arg213
(Figure S1). Interestingly, there is significant conformational vari-
ability in these residues in the various flavivirus structures, re-
flecting the absence of RNA in most of these structures. The
ZIKV NS5-MTase structures superimpose very well on MTase
structures from other flaviviruses (Figure S2). Most of the main-
chain variability is in three solvent exposed loops (residues 48–
52, 173–178, and 244–251) that diverge the most in sequence
(Figures S1 and S2). Curiously, the ZIKV MTase contains Ala21
and Leu22 near the 7-MeGpp binding site (Figure S1) insteadof Arg/Lys and Glu/Arg/Lys/Ser in other flaviviruses, which lends
to a slightly more hydrophobic GTP binding pocket. Ala21 and
Leu22 are conserved in every strain of ZIKV that has been exam-
ined thus far. The ZIKV MTase is also notable in containing
Thr188 and Ser189 instead of Met and Pro in other flaviviruses,
which manifests in a small shift in helix aE (Figure S2).
DISCUSSION
Here, we present two high-resolution crystal structures of
ZIKV NS5-MTase: one with SAM bound to the enzyme, and
the other with both SAM and 7-MeGpp bound to the enzyme
as a mimic of the substrate complex (without RNA) for the
N7MeGpppA-RNA/ N7MeGpppA20OMe-RNA step of the reaction.
Because of the necessity of N7 methylation, the ZIKV NS5-
MTase presents an attractive target for the development of inhib-
itors. One challenge is the design of inhibitors that are specific for
a flavivirus MTase without affecting the host RNA MTases, such
as the human mRNA cap guanine-N7 methyltransferase (RNMT;
PDB: 3EPP) and the MTase domain of human TAR (HIV-1) RNA
binding protein 1 (TARBP1; PDB: 2HA8) (Wu et al., 2008) (Figures
3B and 3C). A step in that direction is a reported SAH analog with
a N6 substituent (a benzyl ring) that fits into a hydrophobic cavity
adjacent to the SAM binding pocket (Lim et al., 2011) (Figure 3A).
This hydrophobic cavity is conserved in flavivirus MTases (Lim
et al., 2011) (including ZIKV) but is not found in human N7/20O
MTases (Figure 3). From the structures, another approach is to
develop SAM/SAH analogs with functionalities that access the
positively chargedRNA binding tunnel (Figure 3A). The tunnel ex-
tends from the SAM binding pocket and substituents on the Cb
atom of the methionine portion of SAM/SAH would be well posi-
tioned to enter the RNA binding tunnel and interact with flavivirus
specific residues (Figure 3A). The emerging role of histone meth-
yltransferases in cancer has spurred the development of new
SAM competitors (Kaniskan and Jin, 2015; Luo, 2012), including
some SAM/SAH analogs (Daigle et al., 2011). Some of these
compounds have entered clinical trials for various cancer malig-
nancies; it will be interesting to see whether any of these com-
pounds can also inhibit the ZIKV MTase.
In conclusion, the high-resolution structures of ZIKV NS5-
MTases presented here provide a basis for structure-based anti-
viral drug discovery. The SAM and GTP binding pockets and the
RNA binding tunnel present hotspots for in silico and fragment
based screening. From the structures, SAM/SAH analogs with
functionalities on the Cb atom of the methionine portion of the
molecules can potentially co-occupy the RNA binding tunnel
and provide better specificity against human RNA MTases.
EXPERIMENTAL PROCEDURES
ZIKV NS5-MTase (1–266) from the H/PF/2013 strain was expressed and puri-
fied from E. coli strain LOBSTR (DE3) with an N-terminal His6-SUMO tag. Cell
pellets containing the recombinant protein were resuspended in buffer con-
taining 50% B-PER (Thermo Scientific), 25 mM Tris pH 8.0, 500 mM NaCl,
5%glycerol, and 5mM2-mercaptoethanol (BME). Cells were lysed by sonicat-
ion and the filtered lysate was loaded on a 5 ml Ni-NTA column (QIAGEN).
Protein bound to the Ni-NTA column was eluted with buffer containing
50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 5% glycerol, 5 mM BME and
250 mM imidazole. Eluted protein was dialyzed into buffer containing 50 mMCell Reports 16, 3097–3102, September 20, 2016 3099
Figure 3. Comparison between ZIKV NS5-
MTase and Human RNA MTases
(A) ZIKV NS5-MTase shown with secondary
structure (left) and electrostatic surface (right).
The secondary structure elements corresponding
to the MTase core is colored cyan, whereas
the secondary structure elements from N- and
C-termini are colored yellow. Blue and red colors
on the electrostatic surface indicate positive and
negative electrostatic potential, respectively. SAM
and 7-MeGpp are shown in magenta. The hydro-
phobic cavity adjacent to the N6 atom on adenine
of SAM is labeled (Lim et al., 2011). The RNA
binding tunnel adjacent to the methionine portion
(and atom Cb) of SAM is also labeled.
(B) Human mRNA cap guanine-N7 methyltransfer-
ase (RNMT; PDB: 3EPP) shown with secondary
structure (left) and electrostatic surface (right). The
protein is aligned to the central b sheet of the ZIKV
NS5-MTase core. Sinefungin (SFG) is shown in
magenta.
(C) The MTase domain of human TAR (HIV-1)
RNA binding protein 1 (TARBP1; PDB: 2HA8)
(Wu et al., 2008). The protein is aligned to the
central b sheet of the ZIKV NS5-MTase core.
S-adenosylhomocysteine (SAH) is shown in
magenta.HEPES (pH 7.5), 500 mM NaCl, 5% glycerol, and 5 mM BME. The His6-SUMO
tag was cleaved with Ulp protease and the protein re-loaded on the Ni-NTA
column to remove the cleaved His6-SUMO tag and any uncleaved protein.
The cleaved protein was further purified by ion exchange chromatography
on an anion exchange column and by size exclusion chromatography on a
SD75 column (GE Healthcare). Before crystallization, the protein was concen-
trated to 10 mg/mL in buffer containing 25 mMHEPES (pH 7.5), 400 mMNaCl,
5% glycerol, and 2 mM TCEP.
The NS5-MTaseSAM crystals grew out of drops containing 17%–20% PEG
400 and 0.1 M Tris (pH 8.0). For data collection, crystals were cryoprotected
by quick dipping in mother liquor containing a mixture of 9% sucrose, 2%
glucose, 8% glycerol, and 8% ethylene glycol and flash-cooled in liquid nitro-
gen. Diffraction data were collected at the Advanced Photon Source (beamline
24-ID-C). The data were indexed with HKL2000 (Otwinowski andMinor, 1997),
and the structure was solved by molecular replacement with Auto-Rickshaw
(http://webapps.embl-hamburg.de/cgi-bin/Auto-Rick/arinitAR1.cgi) (Panjikar
et al., 2005). The model obtained from the Auto-Rickshaw pipeline was
improved by iterative manual building and refinement with Coot (Emsley and3100 Cell Reports 16, 3097–3102, September 20, 2016Cowtan, 2004) and Phenix (Adams et al., 2010),
respectively. After the protein chain was built, sig-
nificant difference electron density (3s) was visible
in the SAH/SAM binding site (Figure 1A). The elec-
tron density was consistent with the presence of
SAH/SAM despite no intentional addition of the
ligand in the purification or crystallization buffers.
This difference density was modeled as SAM,
but the slightly lower occupancy of the methyl
group (75% occupancy) is suggestive of pre-
dominantly SAM with a small amount of SAH in
the crystallized protein. The structure of NS5-
MTaseSAM was refined to 1.33 A˚ (Rfree of 18.9%
and Rwork of 17.0%) and contains one protein
chain, one SAM molecule, one phosphate ion,
one chlorine atom, and 299 solvent molecules.
The model has excellent stereochemistry, as
shown by MolProbity (Davis et al., 2007), with98.1% of all residues in allowed regions of the Ramachandran plot and no
residues in the disallowed regions.
To obtain crystals of The NS5-MTaseSAM,7-MeGpp, purified protein at
0.5 mM concentration was mixed with 3 mM SAM and 3 mM 7-MeGpp prior
to crystallization. Crystals used for data collection grew out of drops contain-
ing 6%–9% PEG 8K, 0.07 M sodium acetate (pH 5.0), and 30% glycerol. For
data collection, crystals were flash-cooled in liquid nitrogen directly from the
drops. Diffraction data were collected at the Advanced Photon Source
(beamline 23-ID-D). The data were indexed with iMOSFLM (Battye et al.,
2011), and the structure was solved by molecular replacement using Auto-
Rickshaw. The model obtained from Auto-Rickshaw was improved by itera-
tive manual building and refinement with Coot and Phenix, respectively.
Clear electron density was visible for both SAM and 7-MeGpp (Figure 1B).
Although the density for the base and sugar of 7-MeGpp was well defined,
the density for the b-phosphate was not as clear. Based on the shape of
the density, we modeled the b-phosphate in two conformations with 70%
and 30% occupancies (Figure S3). The structure of NS5-MTaseSAM,7-MeG
was refined to 1.5 A˚ (Rfree of 17.9% and Rwork of 15.9%) and contains
one protein chain, one SAM molecule, one 7-MeGpp molecule, four glycerol
molecules, one phosphate ion, one acetate ion, and 244 solvent molecules.
The stereochemistry of the protein is excellent, with 98.1% of the residues in
the most favored regions of the Ramachandran plot and none in the disal-
lowed regions.
PyMol (https://www.pymol.org/) was used to compute qualitative surface
electrostatic potential and prepare figures. The potential range was set the
same for all the structures; positive potential is shown in blue, and negative
potential is shown in red.
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